Aesthetic Medical Devices / Non-Invasive Dermatology
Strategic Profile
SofWave demonstrated exceptional growth momentum with 2025 revenue of $87.3-87.6 million, up approximately 46% year-over-year from $59.7 million in 2024. The company is evaluating a potential U.S. public offering and approved submission of a confidential Form F-1 Registration Statement to the SEC in January 2026.
Cyborg Score Rationale
SofWave exhibits strong fundamentals with 46% YoY revenue growth, expanding cash position, FDA-cleared flagship product, and leadership by industry veteran executives. Primary headwinds include valuation premium relative to peer benchmarks and execution risk on U.S. IPO transition.
Top Insights
Explosive growth acceleration: Q4 2025 revenue of $28.6-28.9M (+57% YoY) significantly outpaced full-year growth of 46%, signaling strengthening market demand and operational scaling
U.S. market expansion: Confidential Form F-1 filing suggests imminent Nasdaq listing, unlocking access to larger institutional capital pools and enhanced brand recognition in primary aesthetic market
Leadership pedigree: CEO Louis Scafuri and Chairman Dr. Shimon Eckhouse bring decades of medtech experience from Syneron Candela and Lumenis, reducing execution risk
Regulatory footprint: FDA and CE clearance across multiple indications (facial lines, laxity, cellulite, acne scars) provides clinical validation and market credibility versus competitors
Named Competitors
Ultherapy — Ultrasound technology for non-invasive skin lifting and tightening
LightSheer/Gentle — Laser and light-based aesthetic devices
Cutera Platform — Multi-platform aesthetic laser and RF systems
Recent Developments
(January 2026) Form F-1 confidential submission approved for potential U.S. public offering to evaluate Nasdaq listing